All News

male.female.sexist.jpg

Should we be using JAKi more in female SpA patients?

d Richard Conway, MBBChBAO, PhD

In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of randomised controlled trials of both TNF inhibitors and IL-17 inhibitors suggest that this phenomenon is also manifested in the responses to these agents; female patients do less well than male patients. The mechanisms behind this remain to be fully elucidated.

Read Article
elderly hands

Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults

d Jiha Lee, MD

As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In RA alone, nearly 40 percent of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental question: do we really know how best to treat older adults with rheumatic diseases?

Read Article
laptop

New Research Demonstrates Impact of RISE Registry Data on Rheumatology Outcomes

d ACR Press Release

New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) registry—the nation’s largest collection of electronic health record data from rheumatology practices—is driving transformative improvements in quality, safety, and patient outcomes across rheumatic and musculoskeletal diseases.

Read Article
GLP-1.pink

GLP-1 Receptor Agonists: Impacts Beyond Metabolism?

d Mrinalini Dey, MD

The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.

Read Article
ACRmtg.jpg (keep)

ACR25 - Day 1 Report

d Jack Cush, MD

ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content. 

Read Article
CART

The Rapidly Evolving Landscape of Cellular and Immune-based Therapies

d Akhil Sood, MD

A transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we treat autoimmune diseases.

Read Article
ACR Best

ACR25 Best Abstracts - Day 1

d Jack Cush, MD

The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expected but some of these are gems.

Read Article
This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG

Links:

David Liew drdavidliew ( View Tweet)
GLP-1 RA meds: we are just starting to see their impact in rheumatoid arthritis. We know metabolic, CV risk in RA, but what to do? RA pts in TriNetX, obese non-diabetic GLP-1 RA reduced 1y CV events & also all-cause mortality Soon will be near-standard #ACR25 ABST0445 @RheumNow https://t.co/4ptAHdmf9q

Links:

David Liew drdavidliew ( View Tweet)
Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBest https://t.co/Xa97O6RdBY

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Crisci et al. from CorEvitas. Alcohol, esp moderate use, associated lower CDAI. Most likely explanation appears to be residual confounders based on impact of adjustments however... @RheumNow #ACR25 Abstr#1340 https://t.co/cd0JLW8nGD

Links:

Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any new biomarker which can link these ILD? Measuring reactivity to MDA5 (aa 201-300) epitope peptide may help identify poor ILD prognostics (with/out DM) @RheumNow https://t.co/rziwihKfIr

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs, 3/4 F ?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant Same as Ont, Canada #SSc-ILD % Not rare #ACR25 @RheumNow @ACRheum Abst#0154 https://t.co/imfSyOtYpC

Links:

Janet Pope Janetbirdope ( View Tweet)
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in 50% 14% mild 19% moderate 17% severe Estimated prevalence 36% No correlation between OSA and PsA disease activity or comorbidities But small cohort! https://t.co/VKe7qcHIRm

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3 days -Ability to redose in partial responder @RheumNow https://t.co/pbem7A5Iq5

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel better” Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on. #ACR25 @RheumNow https://t.co/FN3EEowkDP

Links:

sheila RHEUMarampa ( View Tweet)
Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos. #ACR25 @RheumNow https://t.co/sEGXzd8RiD

Links:

sheila RHEUMarampa ( View Tweet)
What are the RFs for progression of Pso to PsA? 🔸PsO disease severity - 3.2x risk —>PsA 🔸Phenotype - nail involvement 🔸Obesity - 6x higher risk of developing PsA 🔸MSK symptoms - arthralgia & heel pain #ACR25 @RheumNow https://t.co/UPXuxBPyKI

Links:

sheila RHEUMarampa ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×